Form 4 for HUMA Humacyte, Inc.
Accepted 2023-03-02 00:00:00 ET · period of report 2023-03-01 · accession 0001818382-23-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-03-02 | 2023-03-01 | HUMA | Niklason Laura E | Pres, CEO, Dir, 10% | M - OptEx | $1.19 | +100.0K | 1.27M | +9% | +$119.0K |
| D | 2023-03-02 | 2023-03-01 | HUMA | Niklason Laura E | Pres, CEO, Dir, 10% | M - OptEx | $0.00 | -100.0K | 162.6K | -38% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-03-01 | M | A | 100,000 | $1.19 | 1,270,240 | D | — | — | |
| 2 | Derivative | Stock Options (right to buy) | 2023-03-01 | M | D | 100,000 | $0.00 | 162,596 | D | $1.19 · 2016-11-22 to 2023-11-23 | 100,000 Common Stock |